Brenus Pharma
PrivateLast Round
Series A
Sep 18, 2024
Total Funding Raised
$34.87M
Momentum Score
75 /100
Company Overview
Brenus Pharma is a clinical-stage biotechnology company focused on preventing cancer recurrence by developing a new generation of cancer vaccines. The company's proprietary 'Stimulated-Tumor-(ghost)-Cells' (STC) platform generates 'off-the-shelf' allogeneic immunotherapies. This technology mimics the conditions of tumor relapse to educate the patient's immune system to anticipate, target, and destroy cancer cells. Their lead candidate, STC-1010, is a therapeutic vaccine targeting metastatic colorectal cancer, the second deadliest cancer worldwide. The company raised approximately $25 million in a Series A round in September 2024 to advance its clinical trials.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Brenus Pharma Comps
Public and private peers based on sector, stage, and business model.
Brenus Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 18, 2024 | ||||
| Grant | Jan 22, 2024 | ||||
| Seed | Mar 17, 2022 |
Key People
Founding team and executive leadership
Brenus Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Noshaq | Series A |
| Investsud | Series A |
| Bpifrance | Grant, Seed |
| Kreaxi | Series A |
| Financière Spin-off Luxembourgeoise | Series A |
| Crédit Agricole Création | Series A |
| French Ministry of the Economy, Finance and Industrial and Digital Sovereignty | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Grew 19% QoQ, from 21 to 25 employees.
- Apr 17, 2026
Monthly visitors grew 40% MoM.
Brenus Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Brenus Pharma's valuation, stock price, and market status.
